Curated News
By: NewsRamp Editorial Staff
July 16, 2026

Regentis Biomaterials Gets EU Nod for Next-Gen GelrinC Manufacturing

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Regentis Biomaterials' new process boosts GelrinC yield by 400%, enabling faster European market entry and a competitive edge in the $3B US cartilage repair market.
  • The solvent-free manufacturing process increases production yield 5x from the same volume while improving efficiency, scalability, and safety, with consistent clinical quality.
  • GelrinC regenerates cartilage via a 10-minute procedure, offering an off-the-shelf treatment for 470,000 annual US knee repair cases, improving quality of life.
  • GelrinC is a cell-free hydrogel implant that degrades in the knee, allowing surrounding cells to regrow cartilage in a synchronized process.

Impact - Why it Matters

This approval not only boosts Regentis's production capacity by 400% but also paves the way for the commercial launch of GelrinC in Europe, offering a minimally invasive, off-the-shelf solution for cartilage repair. For patients suffering from knee cartilage damage, this means potential access to a treatment that regenerates tissue without the need for cell extraction or multiple surgeries. The improved manufacturing process could lower costs and increase availability, addressing a large unmet need in orthopedics. Investors should note the potential market opportunity in the $3 billion U.S. cartilage repair market, where no comparable off-the-shelf product exists.

Summary

Regentis Biomaterials (NYSE American: RGNT) has achieved a significant regulatory milestone, receiving approval from the European Notified Body to manufacture its lead product GelrinC(R) using a next-generation solvent-free manufacturing process. This approval supports the product's planned commercial launch in Europe. The new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while enhancing efficiency, scalability, and occupational and environmental safety. Extensive clinical testing has validated consistent product quality and clinical performance.

GelrinC(R) is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. It has already received CE Mark approval in Europe. Regentis plans to support commercialization through its expanding European Centers of Excellence, surgeon training programs, and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan. The company targets a U.S. cartilage repair market valued at approximately $3 billion, with around 470,000 cases of cartilage knee repair annually where no off-the-shelf treatment is currently available.

Regentis Biomaterials is a regenerative medicine company focused on innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue, including inflamed cartilage and bone. The company's lead product, GelrinC(R), is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled, synchronous process. This advancement could address a significant unmet medical need in orthopedic treatments. For more details, view the full press release at https://ibn.fm/Ths4h.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Regentis Biomaterials Gets EU Nod for Next-Gen GelrinC Manufacturing

blockchain registration record for this content.